Table 1 Clinical information of the patients with HCC and the comparability of the groups
Variable | All group (n = 485) | Validation group (n = 242) | Training group (n = 243) | P-value |
|---|---|---|---|---|
Age | ||||
≤ 65 | 232 (47.84%) | 117 (48.35%) | 115 (47.33%) | 0.9347 |
> 65 | 138 (28.45%) | 71 (29.34%) | 67 (27.57%) | – |
Unknown | 115 (23.71%) | 54 (22.31%) | 61 (25.1%) | – |
Sex | ||||
Female | 121 (24.95%) | 69 (28.51%) | 52 (21.4%) | 0.1197 |
Male | 249 (51.34%) | 119 (49.17%) | 130 (53.5%) | – |
Unknown | 115 (23.71%) | 54 (22.31%) | 61 (25.1%) | – |
Grades | ||||
G1 | 55 (11.34%) | 28 (11.57%) | 27 (11.11%) | 0.9199 |
G2 | 177 (36.49%) | 89 (36.78%) | 88 (36.21%) | – |
G3 | 121 (24.95%) | 63 (26.03%) | 58 (23.87%) | – |
G4 | 12 (2.47%) | 5 (2.07%) | 7 (2.88%) | – |
Unknown | 120 (24.74%) | 57 (23.55%) | 63 (25.93%) | – |
Stages | ||||
Stage I | 226 (46.6%) | 115 (47.52%) | 111 (45.68%) | 0.7997 |
Stage II | 120 (24.74%) | 34 (23.97%) | 62 (25.51%) | – |
Stage III | 106 (21.86%) | 52 (21.49%) | 54 (22.22%) | – |
Stage IV | 8 (1.65%) | 3 (1.23%) | 5 (2.05%) | – |
Unknown | 25 (5.16%) | 14 (5.79%) | 11 (4.53%) | – |
T stages | ||||
T1 | 181 (37.32%) | 98 (40.5%) | 83 (34.16%) | 0.5909 |
T2 | 93 (19.18%) | 46 (19.01%) | 47 (19.34%) | — |
T3 | 80 (16.5%) | 38 (15.71%) | 42 (17.29%) | – |
T4 | 13 (2.68%) | 5 (2.07%) | 8 (3.29%) | – |
Unknown | 118 (24.33%) | 55 (22.72%) | 63 (25.93%) | – |
M stages | ||||
MO | 266 (71.89%) | 129 (53.31%) | 137 (56.38%) | 0.3493 |
M1 | 4 (1.08%) | 2 (0.83%) | 2 (0.82%) | – |
Unknown | 215 (50.74%) | 111 (45.86%) | 104 (42.8%) | – |
N stages | ||||
NO | 252 (51.96%) | 123 (50.83%) | 129 (53.09%) | 0.1049 |
N1 | 4 (0.82%) | 4 (1.65%) | 0 (0%) | – |
Unknown | 229 (47.22%) | 115 (47.52%) | 114 (46.91%) | – |